S&P 500   4,671.61 (+1.68%)
DOW   35,251.71 (+1.01%)
QQQ   399.76 (+2.19%)
AAPL   160.60 (+2.42%)
MSFT   337.70 (+2.43%)
FB   338.30 (+1.55%)
GOOGL   2,910.18 (+2.34%)
AMZN   3,587.68 (+2.37%)
TSLA   1,141.09 (+5.47%)
NVDA   328.62 (+4.31%)
BABA   131.90 (-1.09%)
NIO   40.14 (+0.38%)
CGC   11.15 (-4.62%)
AMD   159.52 (+3.04%)
GE   98.52 (+0.70%)
MU   84.98 (+1.87%)
T   24.00 (-0.91%)
F   19.81 (+0.30%)
DIS   147.12 (-0.67%)
ACB   6.49 (-4.42%)
AMC   36.88 (-1.99%)
PFE   53.76 (-0.44%)
BA   198.24 (-0.49%)
S&P 500   4,671.61 (+1.68%)
DOW   35,251.71 (+1.01%)
QQQ   399.76 (+2.19%)
AAPL   160.60 (+2.42%)
MSFT   337.70 (+2.43%)
FB   338.30 (+1.55%)
GOOGL   2,910.18 (+2.34%)
AMZN   3,587.68 (+2.37%)
TSLA   1,141.09 (+5.47%)
NVDA   328.62 (+4.31%)
BABA   131.90 (-1.09%)
NIO   40.14 (+0.38%)
CGC   11.15 (-4.62%)
AMD   159.52 (+3.04%)
GE   98.52 (+0.70%)
MU   84.98 (+1.87%)
T   24.00 (-0.91%)
F   19.81 (+0.30%)
DIS   147.12 (-0.67%)
ACB   6.49 (-4.42%)
AMC   36.88 (-1.99%)
PFE   53.76 (-0.44%)
BA   198.24 (-0.49%)
S&P 500   4,671.61 (+1.68%)
DOW   35,251.71 (+1.01%)
QQQ   399.76 (+2.19%)
AAPL   160.60 (+2.42%)
MSFT   337.70 (+2.43%)
FB   338.30 (+1.55%)
GOOGL   2,910.18 (+2.34%)
AMZN   3,587.68 (+2.37%)
TSLA   1,141.09 (+5.47%)
NVDA   328.62 (+4.31%)
BABA   131.90 (-1.09%)
NIO   40.14 (+0.38%)
CGC   11.15 (-4.62%)
AMD   159.52 (+3.04%)
GE   98.52 (+0.70%)
MU   84.98 (+1.87%)
T   24.00 (-0.91%)
F   19.81 (+0.30%)
DIS   147.12 (-0.67%)
ACB   6.49 (-4.42%)
AMC   36.88 (-1.99%)
PFE   53.76 (-0.44%)
BA   198.24 (-0.49%)
S&P 500   4,671.61 (+1.68%)
DOW   35,251.71 (+1.01%)
QQQ   399.76 (+2.19%)
AAPL   160.60 (+2.42%)
MSFT   337.70 (+2.43%)
FB   338.30 (+1.55%)
GOOGL   2,910.18 (+2.34%)
AMZN   3,587.68 (+2.37%)
TSLA   1,141.09 (+5.47%)
NVDA   328.62 (+4.31%)
BABA   131.90 (-1.09%)
NIO   40.14 (+0.38%)
CGC   11.15 (-4.62%)
AMD   159.52 (+3.04%)
GE   98.52 (+0.70%)
MU   84.98 (+1.87%)
T   24.00 (-0.91%)
F   19.81 (+0.30%)
DIS   147.12 (-0.67%)
ACB   6.49 (-4.42%)
AMC   36.88 (-1.99%)
PFE   53.76 (-0.44%)
BA   198.24 (-0.49%)
NASDAQ:ELOX

Eloxx Pharmaceuticals Stock Forecast, Price & News

$0.70
+0.01 (+1.45%)
(As of 11/29/2021 12:07 PM ET)
Add
Compare
Today's Range
$0.69
$0.72
50-Day Range
$0.66
$1.85
52-Week Range
$0.63
$6.77
Volume
5,945 shs
Average Volume
882,826 shs
Market Capitalization
$60.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.28
30 days | 90 days | 365 days | Advanced Chart
Receive ELOX News and Ratings via Email

Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Eloxx Pharmaceuticals logo

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA.

Headlines

Eloxx Pharmaceuticals (NASDAQ:ELOX) Price Target Cut to $2.00
November 11, 2021 |  americanbankingnews.com
Eloxx Pharmaceuticals (NASDAQ:ELOX) Issues Quarterly Earnings Results
November 10, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ELOX
Employees
25
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.38 per share

Profitability

Net Income
$-34.58 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
56,409,000
Market Cap
$60.38 million
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

1.77 out of 5 stars

Medical Sector

847th out of 1,392 stocks

Commercial Physical Research Industry

12th out of 27 stocks

Analyst Opinion: 3.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Eloxx Pharmaceuticals (NASDAQ:ELOX) Frequently Asked Questions

Is Eloxx Pharmaceuticals a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Eloxx Pharmaceuticals stock.
View analyst ratings for Eloxx Pharmaceuticals
or view top-rated stocks.

How has Eloxx Pharmaceuticals' stock been impacted by COVID-19?

Eloxx Pharmaceuticals' stock was trading at $2.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ELOX stock has decreased by 75.7% and is now trading at $0.70.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals saw a decline in short interest during the month of October. As of October 15th, there was short interest totaling 639,100 shares, a decline of 25.0% from the September 30th total of 852,300 shares. Based on an average daily trading volume, of 547,100 shares, the short-interest ratio is currently 1.2 days. Currently, 2.1% of the shares of the stock are short sold.
View Eloxx Pharmaceuticals' Short Interest
.

When is Eloxx Pharmaceuticals' next earnings date?

Eloxx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Eloxx Pharmaceuticals
.

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.14) by $0.03.
View Eloxx Pharmaceuticals' earnings history
.

What price target have analysts set for ELOX?

4 Wall Street analysts have issued 1-year price objectives for Eloxx Pharmaceuticals' shares. Their forecasts range from $1.00 to $5.00. On average, they anticipate Eloxx Pharmaceuticals' share price to reach $3.28 in the next year. This suggests a possible upside of 367.9% from the stock's current price.
View analysts' price targets for Eloxx Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Eloxx Pharmaceuticals' key executives?

Eloxx Pharmaceuticals' management team includes the following people:
  • Sumit Aggarwal, President, Chief Executive Officer & Director
  • Daniel E. Geffken, Chief Financial & Accounting Officer
  • Vijay Modur, Head-Research & Development
  • Ali Hariri, Chief Medical Officer
  • Barbara Ryan, Investor Relations Contact

What is Robert E. Ward's approval rating as Eloxx Pharmaceuticals' CEO?

2 employees have rated Eloxx Pharmaceuticals CEO Robert E. Ward on Glassdoor.com. Robert E. Ward has an approval rating of 49% among Eloxx Pharmaceuticals' employees. This puts Robert E. Ward in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What is Eloxx Pharmaceuticals' stock symbol?

Eloxx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ELOX."

Who are Eloxx Pharmaceuticals' major shareholders?

Eloxx Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Altium Capital Management LP (1.30%), Geode Capital Management LLC (0.90%), Two Sigma Advisers LP (0.82%), BlackRock Inc. (0.57%), Vanguard Capital Wealth Advisors (0.51%) and Two Sigma Investments LP (0.37%). Company insiders that own Eloxx Pharmaceuticals stock include Pontifax Management 4 GP (20 and Rajesh B Parekh.
View institutional ownership trends for Eloxx Pharmaceuticals
.

Which institutional investors are selling Eloxx Pharmaceuticals stock?

ELOX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, and Citadel Advisors LLC.
View insider buying and selling activity for Eloxx Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Eloxx Pharmaceuticals stock?

ELOX stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Altium Capital Management LP, Vanguard Capital Wealth Advisors, BlackRock Inc., Geode Capital Management LLC, Two Sigma Investments LP, Natixis, and Bank of New York Mellon Corp. Company insiders that have bought Eloxx Pharmaceuticals stock in the last two years include Pontifax Management 4 GP (20, and Rajesh B Parekh.
View insider buying and selling activity for Eloxx Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eloxx Pharmaceuticals' stock price today?

One share of ELOX stock can currently be purchased for approximately $0.70.

How much money does Eloxx Pharmaceuticals make?

Eloxx Pharmaceuticals has a market capitalization of $60.38 million. The company earns $-34.58 million in net income (profit) each year or ($1.02) on an earnings per share basis.

How many employees does Eloxx Pharmaceuticals have?

Eloxx Pharmaceuticals employs 25 workers across the globe.

What is Eloxx Pharmaceuticals' official website?

The official website for Eloxx Pharmaceuticals is www.eloxxpharma.com.

Where are Eloxx Pharmaceuticals' headquarters?

Eloxx Pharmaceuticals is headquartered at 950 WINTER STREET, WALTHAM MA, 02451.

How can I contact Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals' mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The company can be reached via phone at (781) 577-5300, via email at [email protected], or via fax at 908-864-4440.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.